Gene · 586
Papers1,410
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,410
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Long noncoding RNA TMPO-AS1 upregulates BCAT1 expression to promote cell proliferation in nasopharyngeal carcinoma via microRNA let-7c-5p. | Genes Environ | 2024 | 38937856 | PubTator, text mining | PubMed |
| A glutamatergic biomarker panel enables differentiating Grade 4 gliomas/astrocytomas from brain metastases. | Front Oncol | 2024 | 38835368 | PubTator, text mining | PubMed |
| RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia. | Br J Haematol | 2024 | 38802066 | PubTator, text mining | PubMed |
| Targeted inhibition of branched-chain amino acid metabolism drives apoptosis of glioblastoma by facilitating ubiquitin degradation of Mfn2 and oxidative stress. | Biochim Biophys Acta Mol Basis Dis | 2024 | 38718847 | PubTator, text mining | PubMed |
| BCAT1, IKZF1 and SEPT9: methylated DNA biomarkers for detection of pan-gastrointestinal adenocarcinomas. | Biomarkers | 2024 | 38644767 | PubTator, text mining | PubMed |
| Cross-talk between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination degradation of BCAT1 promotes GBM progression. | Cancer Lett | 2024 | 38621458 | PubTator, text mining | PubMed |
| Metabolic remodeling by the PD-L1 inhibitor BMS-202 significantly inhibits cell malignancy in human glioblastoma. | Cell Death Dis | 2024 | 38438374 | PubTator, text mining | PubMed |
| Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer. | Biomark Insights | 2024 | 38426070 | PubTator, text mining | PubMed |
| Slowing reproductive ageing by preserving BCAT-1. | Nat Metab | 2024 | 38418584 | PubTator, text mining | PubMed |
| HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1. | J Transl Med | 2024 | 38369471 | PubTator, text mining | PubMed |
| High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response. | J Mol Med (Berl) | 2024 | 38340163 | PubTator, text mining | PubMed |
| APOB is a potential prognostic biomarker in hepatocellular carcinoma. | Discov Oncol | 2024 | 38310202 | PubTator, text mining | PubMed |
| Integrated single-cell and bulk characterization of branched chain amino acid metabolism-related key gene BCAT1 and association with prognosis and immunogenicity of clear cell renal cell carcinoma. | Aging (Albany NY) | 2024 | 38309289 | PubTator, text mining | PubMed |
| LncRNA PSMB8-AS1 increases glioma malignancy via the miR-382-3p/BCAT1 axis. | Transl Oncol | 2024 | 38235619 | PubTator, text mining | PubMed |
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. | BMC Cancer | 2024 | 38225589 | PubTator, text mining | PubMed |
| Methylated BCAT1/IKZF1 DNA: a breakthrough in colorectal cancer diagnosis? | Ann Med Surg (Lond) | 2024 | 38222695 | PubTator, text mining | PubMed |
| Amino acid metabolism in tumor biology and therapy. | Cell Death Dis | 2024 | 38218942 | PubTator, text mining | PubMed |
| Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response. | Mol Ther Nucleic Acids | 2024 | 38187140 | PubTator, text mining | PubMed |
| Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groups. | EBioMedicine | 2024 | 38184938 | PubTator, text mining | PubMed |
| FLOT2 promotes nasopharyngeal carcinoma progression through suppression of TGF-β pathway via facilitating CD109 expression. | iScience | 2024 | 38161417 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/586/papers?page=7